AbD Serotec, MorphoSys' division for research and diagnostic antibodies, is set to introduce a series of the human combinatorial antibody library (HuCAL) anti-drug antibodies supporting the development of novel antibody therapeutics.
The company plans to expand the product category with antibodies against Alemtuzumab (Campath), Bevacizumab (Avastin), Infliximab (Remicade), Ustekinumab (Stelara) and Adalimumab (Humira) shortly.
AbD Serotec head Dieter Feger said that anti-drug antibodies are ideal for preclinical and clinical research to support the development of novel antibody drugs as well as biosimilars.
"Due to the recombinant nature of our HuCAL technology, AbD Serotec is able to deliver an unlimited, secure and batch to batch consistent supply of these assay reagents for extensive clinical studies," Feger added.
The HuCAL can deliver highly specific, high-affinity monoclonal antibodies against any given antibody drug with unprecedented success rates and are developed solely in vitro, pre-adsorbed against any available controls and human serum.